264 related articles for article (PubMed ID: 33767059)
1. Apolipoprotein L1 and mechanisms of kidney disease susceptibility.
Bruggeman LA; Sedor JR; O'Toole JF
Curr Opin Nephrol Hypertens; 2021 May; 30(3):317-323. PubMed ID: 33767059
[TBL] [Abstract][Full Text] [Related]
2. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
3. APOL1 variant-associated kidney disease: from trypanosomes to podocyte cytoskeleton.
Pays E
Kidney Int; 2020 Dec; 98(6):1373-1377. PubMed ID: 32835731
[No Abstract] [Full Text] [Related]
4. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
5. APOL1 at 10 years: progress and next steps.
Freedman BI; Kopp JB; Sampson MG; Susztak K
Kidney Int; 2021 Jun; 99(6):1296-1302. PubMed ID: 33794228
[TBL] [Abstract][Full Text] [Related]
6. APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?
Bruggeman LA; O'Toole JF; Sedor JR
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F1-F8. PubMed ID: 30332315
[TBL] [Abstract][Full Text] [Related]
7.
Friedman DJ; Pollak MR
Annu Rev Physiol; 2020 Feb; 82():323-342. PubMed ID: 31710572
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
[TBL] [Abstract][Full Text] [Related]
9. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.
Wakashin H; Heymann J; Roshanravan H; Daneshpajouhnejad P; Rosenberg A; Shin MK; Hoek M; Kopp JB
BMC Nephrol; 2020 Aug; 21(1):371. PubMed ID: 32854642
[TBL] [Abstract][Full Text] [Related]
10. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.
Lannon H; Shah SS; Dias L; Blackler D; Alper SL; Pollak MR; Friedman DJ
Kidney Int; 2019 Dec; 96(6):1303-1307. PubMed ID: 31611067
[TBL] [Abstract][Full Text] [Related]
12. APOL1 Kidney Risk Variants Induce Cell Death
Shah SS; Lannon H; Dias L; Zhang JY; Alper SL; Pollak MR; Friedman DJ
J Am Soc Nephrol; 2019 Dec; 30(12):2355-2368. PubMed ID: 31558683
[TBL] [Abstract][Full Text] [Related]
13. The Relationship between APOL1 Structure and Function: Clinical Implications.
Madhavan SM; Buck M
Kidney360; 2021 Jan; 2(1):134-140. PubMed ID: 35368828
[TBL] [Abstract][Full Text] [Related]
14. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
[TBL] [Abstract][Full Text] [Related]
15. APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ; Pollak MR
Clin J Am Soc Nephrol; 2021 Feb; 16(2):294-303. PubMed ID: 32616495
[TBL] [Abstract][Full Text] [Related]
16. Effect of
Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
[TBL] [Abstract][Full Text] [Related]
17. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
18. Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes.
Gupta N; Wang X; Wen X; Moran P; Paluch M; Hass PE; Heidersbach A; Haley B; Kirchhofer D; Brezski RJ; Peterson AS; Scales SJ
J Am Soc Nephrol; 2020 Sep; 31(9):2065-2082. PubMed ID: 32764138
[TBL] [Abstract][Full Text] [Related]
19. Dilemmas and challenges in apolipoprotein L1 nephropathy research.
Kruzel-Davila E; Skorecki K
Curr Opin Nephrol Hypertens; 2019 Jan; 28(1):77-86. PubMed ID: 30431460
[TBL] [Abstract][Full Text] [Related]
20. APOL1 Nephrotoxicity: What Does Ion Transport Have to Do With It?
Olabisi OA; Heneghan JF
Semin Nephrol; 2017 Nov; 37(6):546-551. PubMed ID: 29110762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
